ACAD Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Acadia Pharmaceuticals Inc (ACAD) following the 2026 Q2 hedge fund 13F filings?

As of today, ACAD has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ACAD gained +11.6% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Acadia Pharmaceuticals Inc (ACAD)

338 + Investors. Track Smart Money conviction in ACAD. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — ACAD

Based on 341 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added ACAD than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

341 hedge funds hold ACAD right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +8% more funds vs a year ago

fund count last 6Q

+24 new funds entered over the past year (+8% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟠

More sellers than buyers — 49% buying

161 buying166 selling

Last quarter: 166 funds reduced or exited vs 161 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

⚠️

Fewer new buyers each quarter (-9 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 48 → 60 → 53 → 44. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

57% of holders stayed for 2+ years

■ 57% conviction (2yr+) ■ 24% medium ■ 19% new

194 out of 341 hedge funds have held ACAD for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💎

Buying through price weakness — shares -1%, value -18%

Value

-17%

Last quarter: funds added -1% more shares while total portfolio value only changed -18%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

➡️

Steady discovery — ~44 new funds/quarter

66 → 48 → 60 → 53 → 44 new funds/Q

New funds entering each quarter: 48 → 60 → 53 → 44. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 65% veterans vs 25% newcomers

■ 65% veterans ■ 10% 1-2yr ■ 25% new

Entry-cohort mix of 353 holders: 228 (65%) are 2+ year veterans, 35 entered 1–2 years ago, and 90 (25%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds

55 of 338 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

3.6

out of 10

Low Exit Risk

Exit risk score 3.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	338	335	0.9%
13F Shares	165M	167M	-0.89%
Total Value	$3.64B	$4.43B	-17.85%
New Positions	42	52	-10
Increased Positions	114	121	-7
Closed Positions	39	52	-13
Reduced Positions	125	118	+7
Total Calls	8	8	-
Total Puts	7	8	-12.5%
PUT/CALL Ratio	0.88	1.0	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

338

335

0.9%

13F Shares

165M

167M

-0.89%

Total Value

$3.64B

$4.43B

-17.85%

New Positions

-10

Increased Positions

114

121

-7

Closed Positions

-13

Reduced Positions

125

118

Total Calls

Total Puts

-12.5%

PUT/CALL Ratio

0.88

1.0

Neutral

Institutional Holders (2026 Q2)

338 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ACAD. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 ACAD holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Ishara Investments LP	7.62%	410,000	$10.4M
2	Baker BROS. Advisors LP	5.44%	42,912,904	$1.09B
3	Birchview Capital, LP	2.02%	171,000	$4.3M
4	Verdad Advisers, LP	2.00%	82,629	$2.1M
5	Nan Fung Group Holdings Ltd	1.98%	102,984	$2.6M
6	Rtw Investments, LP	1.54%	7,144,524	$180.8M
7	Braidwell LP	1.54%	1,646,399	$41.7M
8	Sphera Funds Management LTD.	1.18%	356,534	$9.0M
9	Frazier Life Sciences Management, L.P.	0.79%	1,438,198	$36.4M
10	Rice Hall James & Associates, LLC	0.76%	618,887	$15.7M
11	Tetragon Partners GP Ltd	0.67%	167,875	$4.2M
12	Stempoint Capital LP	0.62%	143,167	$3.6M
13	JGP Global Gestao de Recursos Ltda.	0.45%	8,110	$205K
14	Virtus Advisers, LLC	0.43%	44,384	$1.1M
15	Yorktown Management & Research Co Inc	0.39%	25,450	$644K
16	Hussman Strategic Advisors, INC.	0.37%	63,000	$1.6M
17	Virtus Investment Advisers, LLC	0.32%	55,139	$1.4M
18	Logos Global Management LP	0.27%	250,000	$6.3M
19	Phocas Financial Corp.	0.27%	77,245	$2.0M
20	PSP Research LLC	0.27%	19,766	$500K
21	Fieldview Capital Management, LLC	0.24%	33,368	$844K
22	Emerald Investment Advisers, LLC	0.22%	131,752	$3.3M
23	Edgestream Partners, L.P.	0.21%	283,301	$7.2M
24	Kelsey Financial, LLC	0.19%	10,000	$253K
25	Morgan Creek Capital Management, LLC	0.16%	9,395	$238K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Acadia Pharmaceuticals Inc (ACAD)

What does the Smart Money Trend signal show for ACAD?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added ACAD than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ACAD?

More sellers than buyers — 49% buying: Last quarter: 166 funds reduced or exited vs 161 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for ACAD holders?

Strong quality — 38% AUM from major funds: 55 of 338 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held ACAD?

57% of holders stayed for 2+ years: 194 out of 341 hedge funds have held ACAD for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Acadia Pharmaceuticals Inc (ACAD) following the 2026 Q2 hedge fund 13F filings?

As of today, ACAD has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ACAD has gained +11.6% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Acadia Pharmaceuticals Inc (ACAD)

Smart Money Signals — ACAD

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Steady growth — +8% more funds vs a year ago

More sellers than buyers — 49% buying

Fewer new buyers each quarter (-9 vs last Q)

57% of holders stayed for 2+ years

Buying through price weakness — shares -1%, value -18%

Steady discovery — ~44 new funds/quarter

Veteran-anchored — 65% veterans vs 25% newcomers

Strong quality — 38% AUM from major funds

Institutional Sentiment Summary — ACAD

Hedge Fund Ownership: ACAD

Market Analysis: ACAD

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: ACAD

Is It Too Late to Buy Acadia Pharmaceuticals Inc (ACAD) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: ACAD

Statistics: ACAD

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Acadia Pharmaceuticals Inc (ACAD)

Welcome to 13Foresight!